AstraZeneca (AZN) Stock News: Oxford Vaccine Group provides update on corona virus variants

Reuters reporting that Oxford Vaccine Group Chief Pollard says Autumn is the timeline for having new vaccines against variants available for use.
Additional takeaways
Markets, investors and the general public have been keeping a close eye on recent developments in the fight against new strains of the Covid-19 virus.
See also: AstraZeneca plc gains on urgent European demand for its COVID-19 vaccine
Market reaction
AstraZeneca shares are trading 0.6% higher in Wednesdays pre-market at $50.36.
See also: FXStreet New Equities homepage
The author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
This article is for information purposes only. The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice. It is important to perform your own research before making any investment and take independent advice from a registered investment advisor.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to accuracy, completeness, or the suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. The author will not be held responsible for information that is found at the end of links posted on this page.
Premium
You have reached your limit of 3 free articles for this month.
Start your subscription and get access to all our original articles.
Author

Ivan Brian
FXStreet
Ivan Brian started his career with AIB Bank in corporate finance and then worked for seven years at Baxter. He started as a macro analyst before becoming Head of Research and then CFO.

















